Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study

SIMPLE SUMMARY: ALK-rearranged non-small cell lung cancer treatment has radically changed in the last few years thanks to the development of ALK inhibitors, which clearly improved survival. To our knowledge, even though many studies correlate body mass index (BMI) with lung cancer immunotherapy, con...

Descripción completa

Detalles Bibliográficos
Autores principales: Siringo, Marco, Gentile, Gabriella, Caponnetto, Salvatore, Sperduti, Isabella, Santini, Daniele, Cortesi, Enrico, Gelibter, Alain Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340506/
https://www.ncbi.nlm.nih.gov/pubmed/37444532
http://dx.doi.org/10.3390/cancers15133422

Ejemplares similares

Ejemplares similares